TrialReader


Low Versus Standard Volume EXORA Block in Laparoscopic Cholecystectomy

NCT07507799 — Not applicable, Recruiting, 96 participants, Fayoum University Hospital

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Analgesic Efficacy of Low-Volume Versus Standard-Volume 0.25% Bupivacaine for Ultrasound-Guided External Oblique and Rectus Abdominis Plane Block in Laparoscopic Cholecystectomy, A Randomized Non-Inferiority Trial

RegistryNCT07507799
StatusRecruiting
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: quadruple, prevention
Enrollment96 (Estimated)
SponsorFayoum University Hospital (Other)
ConditionsPain, Postoperative, Post Operative Analgesia
InterventionsEXORA block 15, EXORA block 25 (Procedure)
Datesstart 2026-04-12, primary completion 2027-01-01 (estimated), completion 2027-01-02 (estimated), first posted 2026-04-02, last updated 2026-09-02
Locations1 site in Egypt

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Pain, Postoperative All trials for Post Operative Analgesia All trials of EXORA block 15 All trials of EXORA block 25

-Summary

The original EXORA block used high local anesthetic volume (50 mL total), raising concerns about local anesthetic systemic toxicity (LAST). In such a bilaterally administered regional technique, evaluating the efficacy of a reduced-volume approach is warranted to maximize patient safety.

Expand all sections  ·  Collapse all

+Detailed description

Study Design \& Population This is a prospective, randomized, double-blinded trial enrolling patients scheduled for elective laparoscopic cholecystectomy. Following informed consent, patients will be randomly allocated into two equal groups to evaluate different volumes used in a bilateral, ultrasound-guided External Oblique and Rectus Abdominis (EXORA) block.

Interventions Prior to the induction of general anesthesia, patients will receive a bilateral EXORA block using 0.25% bupivacaine.

Group E15: Will receive 15 mL of the local anesthetic on each side. Group E25: Will receive 25 mL of the local anesthetic on each side. Blinding \& Allocation Allocation concealment will be maintained using sequentially numbered, opaque, sealed envelopes. The block will be performed by a designated regional anesthesiologist who will not be involved in subsequent patient care. The patient, the surgical team, the intraoperative anesthesiologist, and the postoperative data collectors will remain strictly blinded to the group allocation and the volume injected.

Anesthesia \& Perioperative Management Sensory block distribution will be assessed prior to surgery. All patients will receive a standardized general anesthesia protocol for induction and maintenance. Intraoperative hemodynamics will be managed according to standard institutional protocols.

Postoperative Analgesia \& Monitoring Upon transfer to the Post-Anesthesia Care Unit (PACU) and throughout the first 24 hours, all patients will receive scheduled, standardized multimodal analgesia (intravenous paracetamol and ketorolac). Postoperative pain will be assessed using the 11-point Numerical Rating Scale (NRS) at rest and during movement at prespecified time points. If the dynamic NRS score is ≥ 4, intravenous morphine (2 mg) will be administered . Patients will be continuously monitored for adverse events, including postoperative nausea and vomiting (PONV), hemodynamic instability, and local anesthetic systemic toxicity (LAST), which will be managed with predefined rescue medications

+Arms and interventions

ArmTypeInterventionsDescription
EXORA 15Active comparatorProcedure: EXORA block 1515 mL of bupivacaine 0.25% administered bilaterally
EXORA 25Active comparatorProcedure: EXORA block 2525 mL of bupivacaine 0.25% administered bilaterally
  • EXORA block 15 (Procedure): 15 mL of bupivacaine 0.25% administered bilaterally by ultrasound guided EXORA block
  • EXORA block 25 (Procedure): 25 mL of bupivacaine 0.25% administered bilaterally by ultrasound guided EXORA block

+Outcome measures

Primary outcomes

  • Dynamic numerical rating scale (NRS) score at 4 hours postoperatively. [4 hours after surgery]: From 0 to 10 where 0 denote no pain and 10 denote the worst pain ever experienced with cough

Secondary outcomes

  • Static Numerical Rating scale NRS scores [up to 24 hours post operatively]: From 0 to 10 where 0 denote no pain and 10 denote the worst pain ever experienced At predefined time points.(1,2,4,6,12 and 24 hours post operatively
  • Dynamic numerical rating scale NRS scores [up to 24 hours post operatively]: From 0 to 10 where 0 denote no pain and 10 denote the worst pain ever experienced With cough at predefined time points.(1,2,6,12 and 24 hours post operatively
  • Cumulative Static Pain Burden [Up to 24h postoperatively]: calculated as the Area Under the Curve (AUC) of Static NRS scores over the 24-hour postoperative period
  • Cumulative Dynamic Pain Burden [Up to 24h postoperatively]: calculated as the Area Under the Curve (AUC) of Dynamic NRS scores over the 24-hour postoperative period
  • Intraoperative Fentanyl consumption Total fentanyl in micrograms [From induction of anesthesia until patient is transferred to postoperative care unit up to 4 hours]]: Total fentanyl in micrograms
  • Total cumulative consumption of intravenous morphine over the first 24 hours. [At 24 hours postoperatively]: total morphine used in milligrams post operatively over 24 hours.
  • Time to first rescue analgesia [Upon recovery from General anesthesia up to 24 hours postoperatively]]: Time to first request of rescue analgesia in hours
  • Sensory block distribution level (pin-prick test) [At 30 minuets from the block]: After 30 minutes of the block, assessed at. Midclavicular and Midaxillary lines from T5 to T12 level by a blinded anesthesiologist
  • Quality of recovery score (QoR-15) at 24 hours. [At 24 hours postoperatively]: scores range from 0 to 150, with a higher score indicating a better quality of postoperative recovery.
  • Incidence of adverse events: bradycardia, hypotension, PONV, and LAST. [From induction of anesthesia up to 24 hours postoperatively]: Assessment of each patient looking for any of adverse effects as bradycardia ,hypotension, nausea, vomiting and LAST.
  • Heart rate [Upon arrival to Operating Room until 24 hours postoperative]: Heart rate measured at Baseline (T0), 3 minutes post-intubation (T1), 1 minute post-skin incision (T2), 5 minutes after pneumoperitoneum inflation (T3), At extubation (T4) and postoperatively upon arrival in the PACU (0 hours), 1, 2, 4, 6, 12, and 24 hours
  • Mean arterial pressure [Upon arrival to Operating Room until 24 hours postoperative]: Mean arterial pressure measured at Baseline (T0), 3 minutes post-intubation (T1), 1 minute post-skin incision (T2), 5 minutes after pneumoperitoneum inflation (T3), At extubation (T4) and postoperatively upon arrival in the PACU (0 hours), 1, 2, 4, 6, 12, and 24 hours
  • Ramsay Sedation Scale (RSS) [up to 24 hours]: from 1 to 6 where 1 denotes anxious/agitated and 6 denotes deep sedation with no response to stimuli (6) assessed postoperative (at 1, 2, 4, 6, 12, and 24 hours)

+Eligibility

Sex: All, ages: 18 Years to 65 Years

Inclusion Criteria:

* American Society of Anesthesiologists (ASA) physical status I or II.
* Scheduled for elective laparoscopic cholecystectomy under general anesthesia.

Exclusion Criteria:

* • Patient refusal to participate.

  * Obese patients with a body mass index of more than 35 kg/m2.
  * Known cognitive impairment or use of psychiatric drugs
  * Known allergy to local anesthetics
  * Infection at the needle insertion site.
  * Coagulopathy, or bleeding disorders.
  * Pregnancy
  * History of chronic pain or chronic opioid use.
  * Previous major upper abdominal surgery (which alters the fascial planes and anatomy).

Criteria for Withdrawal from Study Analysis (Drop-outs):

* Conversion to open cholecystectomy during surgery.
* Failed EXORA block

+Locations (1)

FacilityCityCountryStatus
Fayoum University hospitalEl Fayoum Qesm, Faiyum GovernorateEgyptRecruiting

+Publications

  • Okmen K, Demirel A, Dogan AK, Ertus CY. Application of EXORA block for analgesia following hand-assisted laparoscopic donor nephrectomy (HALDN). Indian J Anaesth. 2025 Mar;69(3):324-326. doi: 10.4103/ija.ija_1263_24. Epub 2025 Feb 17. No abstract available. PMID 40161911
  • Okmen K, Yildiz DK, Ulker GK. Evaluation of the efficacy of M-TAPA and EXORA block application for analgesia after laparoscopic cholecystectomy: a prospective, single-blind, observational study. Korean J Anesthesiol. 2025 Aug;78(4):361-368. doi: 10.4097/kja.24563. Epub 2025 Apr 15. PMID 40230270
  • Fernandez Martin MT, Lopez Alvarez S, Valdes-Vilches LF. EXORA block: a new approach for laparoscopic cholecystectomy analgesia? Minerva Anestesiol. 2024 May;90(5):462-463. doi: 10.23736/S0375-9393.23.17863-1. Epub 2024 Jan 29. No abstract available. PMID 38287777
  • Kumar K, Kirksey MA, Duong S, Wu CL. A Review of Opioid-Sparing Modalities in Perioperative Pain Management: Methods to Decrease Opioid Use Postoperatively. Anesth Analg. 2017 Nov;125(5):1749-1760. doi: 10.1213/ANE.0000000000002497. PMID 29049119
  • De Cassai A, Sella N, Geraldini F, Tulgar S, Ahiskalioglu A, Dost B, Manfrin S, Karapinar YE, Paganini G, Beldagli M, Luoni V, Ordulu BBK, Boscolo A, Navalesi P. Single-shot regional anesthesia for laparoscopic cholecystectomies: a systematic review and network meta-analysis. Korean J Anesthesiol. 2023 Feb;76(1):34-46. doi: 10.4097/kja.22366. Epub 2022 Nov 8. PMID 36345156
  • Ekstein P, Szold A, Sagie B, Werbin N, Klausner JM, Weinbroum AA. Laparoscopic surgery may be associated with severe pain and high analgesia requirements in the immediate postoperative period. Ann Surg. 2006 Jan;243(1):41-6. doi: 10.1097/01.sla.0000193806.81428.6f. PMID 16371735

+Investigators

My Notes